Himisha Beltran
Associate Professor of Medicine at Dana Farber Cancer Institute at Harvard Medical School
Biography
Harvard Medical School
Dr. Himisha Beltran is a medical oncologist who specializes in caring for patients with genitourinary malignancies (prostate cancer, bladder cancer, germ cell tumor, kidney cancer).
Dr. Beltran received her undergraduate degree from the University of Oregon, her medical degree from New York Medical College and completed her residency at Hospital of the University of Pennsylvania and her fellowship in Hematology and Medical Oncology at The New York Hospital-Weill Cornell Medical College. Dr. Beltran is the recipient of numerous awards, including a Prostate Cancer Foundation Young Investigator Award and an AACR Women in Cancer Research Scholar Award.
Dr. Beltran’s clinical specialty is the care of patients with prostate cancer. Her particular focus is next-generation genomic sequencing and integrative molecular analysis of advanced metastatic prostate tumors to develop precision cancer care and biomarker driven clinical trials. Her research has brought increased attention to identifying and targeting androgen receptor (AR) negative neuroendocrine prostate cancer, an aggressive subtype of prostate cancer. Dr. Beltran has developed novel biomarkers and a multi-institutional Phase 2 trial of a targeted therapy for patients with this form of prostate cancer.
She is developing a research program to study the RNA and DNA of neuroendocrine prostate cancer to learn how these cancers evolve, to identify molecular alterations to target with drugs and develop clinical trials to bring new effective therapy to patients. Dr. Beltran is the recipient of numerous awards including a Prostate Cancer Foundation Young Investigator Award, AACR Women in Cancer Research Scholar Award, and Damon Runyon Cancer Foundation Clinical Investigator Award.
Relevant to SPORE Project 1 (Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer) she has used genomics and epigenomics to understand tumor evolution in collaboration with Dr. Demichelis (Co-PI) in advanced prostate cancer. They developed biomarkers to identify patients with neuroendocrine prostate cancer, an aggressive subtype of prostate cancer, that we will further develop non-invasively using ctDNA as part of Project
Relevant to Project 2 (Targeting N-Myc and EZH2-driven Castrate Resistance Prostate Cancer) and in collaboration with Dr. Rickman (Co-PI), she has also identified new therapeutic targets for neuroendocrine prostate cancer. Based on their initial work she is leading an investigator-initiated, national Phase 2 clinical trial of the Aurora A inhibitor MLN8237 for NEPC patients. As Director of Clinical Activities within our Institute for Precision Medicine and through a clinical protocol for metastatic tumor biopsies, her goal is to continue to develop molecularly based treatment approaches for patients. Additionally, Dr. Beltran leads functional validation studies in the laboratory and develops early phase clinical trials based on those targets.
Videos
Divergent Clonal Evolution of Castration Resistant Neuroendocrine Prostate Cancer
What will change for men with advanced prostate cancer in the next 24 months?
December 8, 2020 - Himisha Beltran, MD
How to Engage In Your Prostate Cancer Treatment Decisions
What Is a Prostate Cancer Genetic Mutation?
Dr. Beltran on the Limitations of Tissue Biopsies Versus Liquid Biopsies in CRPC-NE
Dr. Beltran on Using cfDNA to Detect Castration-Resistant Neuroendocrine Prostate Cancer
An Update on Prostate Cancer Treatment and Research
How PCF Changed the Culture of Cancer Research
Himisha Beltran, MD
Dr. Beltran on Use of ctDNA to Evaluate Treatment Resistance in Prostate Cancer
How Do Genetic Mutations Impact Prostate Cancer Treatment Options?
COVID Vaccines: What Do Prostate Cancer Patients Need to Know?
Prostate Cancer Treatment NYC | Weill Cornell Medicine Genitourinary Oncology Program
What Is a Prostate Cancer Biomarker?
Read about executive education
Other experts
Popular Courses
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Sep 8
Leading Strategic Growth and Change
Columbia Business School
New York, New York, United States
Jun 10
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Jun 23
The Manchester Leadership Development Programme
Alliance Manchester Business School
Manchester, United Kingdom
Jul 1
Leading People and Teams
ESMT
Berlin, Germany
May 28
Leading Digital Transformation
ESMT
Berlin, Germany
May 28
Looking for an expert?
Contact us and we'll find the best option for you.